FrancophonIA/ELRC3.0 huggingface dataset:
English: DPD deficiency: if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by Ecansya (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).
Croatian: - nedostatak DPD-a: ako imate nedostatak DPD-a, imate povećan rizik od akutnog ranog nastupa toksičnosti i teških, po život opasnih ili smrtonosnih nuspojava koje uzrokuje lijek Ecansya (npr. stomatitis, upala sluznica, proljev, neutropenija i neurotoksičnost).
English: LIST OF EXCIPIENTS Also contains lactose.
Croatian: Također sadrži laktozu.
English: Time to progressive disease was superior in the capecitabine + docetaxel combination arm (p<0.0001).
Croatian: Vrijeme do progresije bolesti bilo je duže u skupini koja je liječena kombinacijom kapecitabina i docetaksela (p<0,0001).
English: Fatal cases have been reported following this drug interaction.
Croatian: Nakon interakcije ova dva lijeka prijavljeni su smrtni slučajevi.
English: The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from 3.9 to 59.9, n=8) whereas the ratio in healthy tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n=8).
Croatian: Omjer koncentracije 5-FU u tumoru u odnosu na plazmu iznosio je 21,4 (raspon od 3,9 do 5,9; n=8), pri čemu je omjer u zdravim tkivima u odnosu na plazmu iznosio 8,9 (raspon od 3,0 do 25,8; n=8).
English: There is no relevant use of capecitabine in the paediatric population in the indications colon, colorectal, gastric and breast cancer.
Croatian: Nema relevantne primjene kapecitabina u pedijatrijskoj populaciji u indikacijama karcinoma kolona, kolorektalnog karcinoma, karcinoma želuca i karcinoma dojke.
English: This will help reduce the likelihood that the side effect continues or becomes severe.
Croatian: Time će se smanjiti vjerojatnost da se nuspojave produlje i razviju u težem obliku.
English: Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU).
Croatian: Kapecitabin je necitotoksični fluoropirimidin karbamat, koji djeluje kao peroralno primijenjeni prethodnik citotoksične tvari 5-fluorouracila (5-FU).
English: In the study published by Skof et al, patients were randomised to receive either FOLFIRI or XELIRI.
Croatian: U ispitivanju koje su objavili Skof i sur., bolesnici su randomizirani da primaju protokole FOLFIRI ili XELIRI.
English: If no toxicity is observed in patients 60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m2 twice daily.
Croatian: Ako se u tih bolesnika ne uoče znakovi toksičnosti pri primjeni smanjene početne doze kapecitabina u kombinaciji s docetakselom, doza kapecitabina može se oprezno povećavati do 1250 mg/m2 dvaput dnevno.
English: Patients taking phenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
Croatian: U bolesnika koji istodobno uzimaju kapecitabin i fenitoin potrebno je redovito pratiti porast koncentracije fenitoina u plazmi.
English: ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of capecitabine are listed in table 4 for capecitabine given as monotherapy and in table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications.
Croatian: Nuspojave za koje ispitivač smatra da su moguće, vjerojatno ili slabo povezane s primjenom kapecitabina, navedene su u Tablici 4 za kapecitabin u monoterapiji i u Tablici 5 za kapecitabin u različitim kemoterapijskim protokolima u različitim indikacijama.
English: Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus (e.g. DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants), which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of life-threatening or fatal toxicity and should not be treated with Ecansya (see section 4.3).
Croatian: Iako deficit DPD-a nije precizno definiran, poznato je da bolesnici s određenim homozigotnim ili određenim višestrukim heterozigotnim mutacijama u lokusu gena DPYD (npr. varijantama DPYD*2A, c.1679T>G, c.2846A>T i c.1236G>A/HapB3), koje mogu uzrokovati potpun ili gotovo potpun izostanak enzimske aktivnosti DPD-a (određuje se laboratorijskim testovima), imaju najveći rizik od po život opasne ili smrtonosne toksičnosti te se ne smiju liječiti lijekom Ecansya
English: Ophthalmologic complications: Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders.
Croatian: Bolesnike treba pomno nadzirati zbog moguće pojave oftalmoloških komplikacija, poput keratitisa i poremećaja rožnice, osobito ako imaju poremećaje oka u anamnezi.
English: In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.
Croatian: Na ksenograftskim modelima humanog karcinoma kapecitabin je pokazao sinergistički učinak u kombinaciji s docetakselom, što se može dovesti u vezu s povećanjem aktivnosti timidin fosforilaze uzrokovane docetakselom.
English: Exposure to crushed or cut capecitabine tablets:
Croatian: Izlaganje zdrobljenim ili prelomljenim tabletama kapecitabina
English: In patients with unrecognised DPD deficiency treated with capecitabine as well as in those patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
Croatian: U bolesnika s neprepoznatim deficitom DPD-a liječenih kapecitabinom, kao i u onih s negativnim nalazima testova na specifične varijacije gena DPYD, može doći do po život opasne toksičnosti koja se manifestira kao akutno predoziranje (vidjeti dio 4.9).
English: Also, you need to be particularly careful if you are taking any of the following: - gout medicines (allopurinol), - blood-thinning medicines (coumarin, warfarin), - medicines for seizures or tremors (phenytoin), - interferon alpha, - radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab,
Croatian: Također, trebate biti posebno oprezni ako uzimate neki od ovih lijekova: - lijekove za liječenje gihta (alopurinol), - lijekove protiv zgrušavanja krvi (kumarin, varfarin), - lijekove protiv epilepsije ili tremora (fenitoin), - interferon alfa, - ako primate terapiju zračenjem ili uzimate neke lijekove za liječenje raka (folinatna kiselina,
English: ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy (see table 4).
Croatian: Nuspojave su svrstane u odgovarajuće kategorije ukupne učestalosti (vrlo često ili često) prema najvećoj incidenciji primijećenoj u bilo kojem od glavnih ispitivanja i navode se samo ako su dodatno primijećene uz one već zabilježene kod monoterapije kapecitabinom ili ako je njihova učestalost veća u usporedbi s monoterapijom kapecitabinom (vidjeti Tablicu 4).
English: Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
Croatian: Medijan preživljenja iznosio je 442 dana (kombinacija kapecitabina i docetaksela), odnosno 352 dana (samo docetaksel).
English: Phase I studies evaluating the effect of capecitabine on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by capecitabine on the pharmacokinetics of docetaxel or paclitaxel (Cmax and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5'-DFUR.
Croatian: Klinička ispitivanja faze I u kojima se ocjenjivao učinak kapecitabina na farmakokinetiku docetaksela ili paklitaksela i obratno nisu pokazala nikakav učinak kapecitabina na farmakokinetiku docetaksela ili paklitaksela (Cmax i AUC) niti je utvrđen učinak docetaksela ili paklitaksela na farmakokinetiku 5'DFUR.
English: 9/L, treatment with capecitabine should be interrupted.
Croatian: 9/l potrebno je prekinuti liječenje kapecitabinom.
English: The elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.
Croatian: Poluvrijeme eliminacije (t1/2 u satima) kapecitabina, 5'-DFCR, 5'-DFUR, 5-FU i FBAL iznosilo je 0,85; 1,11; 0,66; 0,76 i 3,23.
English: In the absence of safety and efficacy data in patients with hepatic impairment, capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis.
Croatian: Budući da nema podataka o sigurnosti i djelotvornosti primjene lijeka u bolesnika s oštećenjem jetre, primjenu kapecitabina treba pomno nadzirati u bolesnika s blago do umjereno narušenom funkcijom jetre, bez obzira na to ima li bolesnik ili ne jetrene metastaze.
English: Coumarin-derivative anticoagulants: altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
Croatian: Promijenjeni koagulacijski parametri i/ili krvarenje zabilježeni su u bolesnika koji su kapecitabin uzimali istodobno s kumarinskim antikoagulansima, kao što su varfarin i fenprokumon.
English: In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus ≥1).
Croatian: U svim ispitivanjima sljedeći nezavisni čimbenici su bili statistički značajno povezani s povećanim rizikom razvoja sindroma šaka-stopalo: povećana početna doza kapecitabina (u gramima), smanjena kumulativna doza kapecitabina (0,1*kg), povećanje intenziteta relativne doze u prvih šest tjedana, produženje liječenja u ispitivanju (tjedni), starija životna dob (u intervalima od 10 godina), ženski spol i dobar ECOG status na početku liječenja (0 nasuprot ≥
English: The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).
Croatian: Medijan vremena do progresije bolesti iznosio je 186 dana (kombinacija kapecitabina i docetaksela), odnosno 128 dana (samo docetaksel).
English: Capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer.
Croatian: Kapecitabin je u kombinaciji s oksaliplatinom primijenjen i u liječenju uznapredovalog karcinoma želuca.
English: Capecitabine in combination therapy
Croatian: Kapecitabin u kombiniranoj terapiji
English: Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described.
Croatian: U literaturi je opisana klinički značajna interakcija između brivudina i fluoropirimidina (npr. kapecitabina, 5-fluorouracila, tegafura), koja proizlazi iz inhibicije dihidropirimidin dehidrogenaze brivudinom.
English: SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
Croatian: POSEBNO UPOZORENJE O ČUVANJU LIJEKA IZVAN POGLEDA
English: In embryotoxicity and teratogenicity studies in mice, dose-related increases in foetal resorption and teratogenicity were observed.
Croatian: U ispitivanjima embriotoksičnosti i teratogenosti u miševa primijećeni su povećana fetalna resorpcija ovisna o dozi i teratogenost.
English: Capecitabine Monotherapy Table 4 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1900 patients (studies M66001, SO14695, and SO14796).
Croatian: U Tablici 4 nalazi se popis nuspojava povezanih s primjenom kapecitabina u monoterapiji koji se temelji na združenoj analizi sigurnosnih podataka iz tri glavna ispitivanja na više od 1900 bolesnika (M66001, SO14695, SO14796).
English: Each film-coated tablet contains 150 mg, 300 mg or 500 mg capecitabine.
Croatian: Jedna filmom obložena tableta sadrži 150 mg, 300 mg ili 500 mg kapecitabina.
English: There are no side-effects caused by stopping treatment with capecitabine.
Croatian: Nema nuspojava uzrokovanih prestankom liječenja kapecitabinom.
English: 5-FU is further catabolised by the enzyme dihydropyrimidine dehydrogenase (DPD) to the much less toxic dihydro-5-fluorouracil (FUH2).
Croatian: 5-FU se dalje katabolizira u manje toksičan dihidro-5-fluoruracil (FUH2) pomoću enzima dihidropirimidin dehidrogenaze (DPD).
English: Cardiac arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia), angina pectoris, myocardial infarction, heart failure and cardiomyopathy have been reported in patients receiving capecitabine.
Croatian: Srčane aritmije (uključujući fibrilaciju ventrikula, torsade de pointes i bradikardiju), angina pektoris, infarkt miokarda, srčano zatajenje i kardiomiopatija zabilježeni su u bolesnika koji su primali kapecitabin.
English: The median time to progression was 140 days (capecitabine) vs. 144 days (Mayo regimen).
Croatian: Medijan vremena do progresije bolesti iznosio je 140 dana (kapecitabin) u odnosu na 144 dana (Mayo protokol).
English: For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Ecansya are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjustment according to toxicity.
Croatian: U bolesnika s djelomičnim deficitom DPD-a (poput onih s heterozigotnim mutacijama u genu DPYD) i za koje se smatra da koristi liječenja lijekom Ecansya nadmašuju rizike (uzimajući u obzir prikladnost nekog drugog kemoterapijskog protokola koji ne uključuje fluoropirimidin), liječenje treba provoditi uz izniman oprez i sa čestim praćenjem uz prilagodbu doze sukladno toksičnosti.
English: Atrial fibrillation, Cardiac ischaemia/infarction
Croatian: Srčani poremećaji fibrilacija atrija, ishemija miokarda/infarkt
English: Patients treated with XELIRI + bevacizumab reported a significantly higher incidence of diarrhoea, febrile neutropenia and hand-foot skin reactions than patients treated with FOLFIRI + bevacizumab with significantly increased treatment delays, dose reductions and treatment discontinuations.
Croatian: Bolesnici liječeni protokolom XELIRI i bevacizumabom prijavili su značajno veću incidenciju proljeva, febrilne neutropenije i sindroma šaka-stopalo nego bolesnici koji su primali FOLFIRI i bevacizumab, uz značajno više odgoda liječenja, smanjenja doze i prekida liječenja.
English: Median survival was 392 days (capecitabine) vs. 391 days (Mayo regimen).
Croatian: Medijan preživljenja iznosio je 392 dana (kapecitabin) u odnosu na 391 dan (Mayo protokol).
English: Toxcity was similar between treatments with the exception of neutropenia reported more commonly in patients treated with FOLFIRI.
Croatian: Toksičnost je bila podjednaka kod oba režima liječenja, uz izuzetak neutropenije koja je prijavljena češće u bolesnika liječenih FOLFIRI protokolom.
English: No information is available on hepatic impairment due to cirrhosis or hepatitis.
Croatian: Nisu dostupne informacije za bolesnike s oštećenjem funkcije jetre uzrokovanom cirozom ili hepatitisom.
English: XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486) which translates into a 13% reduction in risk of death.
Croatian: XELOX je pokazao trend prema poboljšanju ukupnog preživljenja uz omjer hazarda od 0,87 (95% CI=[0,72; 1,05]; p=0,1486), što znači 13%-tno smanjenje rizika od smrti.
English: In the largest study (BICC-C), patients were randomised to receive either open label FOLFIRI (n=144), bolus 5-FU (mIFL) (n=145) or XELIRI (n=141) and were additionally randomised to receive either double-blind treatment with celecoxib or placebo.
Croatian: U najvećem su ispitivanju (BICC-C) bolesnici randomizirani da otvoreno primaju FOLFIRI protokol (n=144), bolus 5-FU (mIFL) (n=145) ili XELIRI protokol (n=141), a dodatno su randomizirani na dvostruko slijepo liječenje celekoksibom ili placebom.
English: The hazard ratio for overall survival was 0.94 (95% CI: 0.89; 1.00, p=0.0489) indicating that capecitabine-containing regimens are non-inferior to 5-FU-containing regimens.
Croatian: Omjer hazarda za ukupno preživljenje bio je 0,94 (95% CI: 0,89; 1,00, p=0,0489), što pokazuje da protokoli koji sadrže kapecitabin nisu inferiorni u odnosu na protokole koji sadrže 5-FU.
English: Table 7 Key efficacy results for the non-inferiority analysis of Study NO16966 PRIMARY ANALYSIS XELOX/XELOX+P/
Croatian: Tablica 7 Ključni rezultati djelotvornosti iz analize o neinferiornosti u ispitivanju NO16966 PRIMARNA ANALIZA XELOX/XELOX+P/ XELOX+BV (EPP*: N=967; ITT**: N=1017)
English: Colon, colorectal and advanced gastric cancer: meta-analysis A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, M17032) supports capecitabine replacing 5-FU in mono- and combination treatment in gastrointestinal cancer.
Croatian: Karcinom kolona, kolorektalni karcinom i uznapredovali karcinom želuca: metaanaliza Metaanaliza šest kliničkih ispitivanja (SO14695, SO14796, M66001, NO16966, NO16967, M17032) podržava zamjenu 5-FU kapecitabinom u monoterapiji i kombiniranoj terapiji karcinoma probavnog sustava.
English: Survival was superior in the capecitabine + docetaxel combination arm (p=0.0126).
Croatian: Preživljenje je bilo veće u skupini koja je liječena kombinacijom kapecitabina i docetaksela (p=0,0126).
English: Following oral administration of capecitabine to patients with colorectal cancer, the ratio of 5-FU concentration in colorectal tumours to adjacent tissues was 3.2 (ranged from 0.9 to 8.0).
Croatian: Nakon peroralne primjene kapecitabina u bolesnika s kolorektalnim karcinomom omjer koncentracije 5-FU u tkivu kolorektalnog karcinoma u odnosu na okolna tkiva iznosio je 3,2 (raspon od 0,9 do 8,0).
English: When capecitabine was used in combination with other medicinal products, elderly patients (≥65 years) experienced more grade 3 and grade 4 adverse drug reactions, including those leading to discontinuation, compared to younger patients.
Croatian: Pri primjeni kapecitabina u kombinaciji s drugim lijekovima stariji bolesnici (≥ 65 godina) su imali više nuspojava 3. i 4. stupnja nego mlađi, uključujući i one zbog kojih je trebalo prekinuti liječenje.
English: Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products
Croatian: Prilagodbe doze zbog toksičnosti kada se kapecitabin primjenjuje kontinuirano u kombinaciji s drugim lijekovima
English: If you are a woman who could become pregnant you should use effective contraception during treatment with Ecansya and for 6 months after the last dose.
Croatian: Ako ste žena koja može zatrudnjeti, morate koristiti učinkovitu metodu kontracepcije tijekom liječenja lijekom Ecansya i još 6 mjeseci nakon posljednje doze.
English: The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).
Croatian: Incidencija nuspojava 3. i 4. stupnja u bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30-50 ml/min) povećana je u usporedbi s ukupnom populacijom (vidjeti dijelove 4.2 i 4.3).
English: Very rare side effects (may affect up to 1 in 10,000 people) include: - severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes)
Croatian: Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba) su: - teške kožne reakcije poput osipa kože, vrijedova i mjehurića koji mogu obuhvaćati vrijedove u ustima, nosu, spolnim organima, šakama, stopalima i očima (crvene i otečene oči)
English: Combination therapy
Croatian: Kombinirana terapija
English: Oxaliplatin on Day 1, every 3 weeks Capecitabine oral twice daily for 2 weeks (followed by 1 week offtreatment)
Croatian: sata oksaliplatin prvog dana, svaka 3 tjedna kapecitabin oralno dvaput dnevno tijekom 2 tjedna (nakon čega slijedi jedan tjedan pauze)
English: Currently, no comparative data are available on capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens.
Croatian: Za sada nema usporednih podataka monoterapije kapecitabinom i kombinacijskih protokola u prvoj liniji liječenja kolorektalnoga karcinoma.
English: FOLFOX-4+BV (EPP*: N=937; ITT**: N=1017)
Croatian: FOLFOX-4/FOLFOX-4+P/ FOLFOX-4+BV (EPP*: N=937; ITT**: N=1017)
English: In reproductive toxicity studies in animals, capecitabine administration caused embryolethality and teratogenicity.
Croatian: U ispitivanjima reproduktivne toksičnosti na životinjama primjena kapecitabina djelovala je embrioletalno i teratogeno.
English: Following oral administration of 825 mg/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for capecitabine than Caucasian patients (n=22).
Croatian: Faktori etničke pripadnosti: Nakon peroralne primjene 825 mg/m2 kapecitabina dvaput dnevno tijekom 14 dana, Japanci (n=18) su imali 36% niži Cmax i 24% niži AUC kapecitabina nego bijelci (n=22).
English: A comparison of XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab was a pre-specified exploratory analysis.
Croatian: Usporedba XELOX protokola s bevacizumabom u odnosu na FOLFOX-4 protokol s bevacizumabom bila je unaprijed definirana istraživačka analiza.
English: However, folinic acid has an effect on the pharmacodynamics of capecitabine and its toxicity may be enhanced by folinic acid: the maximum tolerated dose (MTD) of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day whereas it is only 2000 mg/m2 per day when capecitabine was combined with folinic acid (30 mg orally bid).
Croatian: Međutim, folinatna kiselina djeluje na farmakodinamiku kapecitabina te njegova toksičnost može biti povećana folinatnom kiselinom: najveća podnošljiva doza (MTD - Maximum tolerated dose) kapecitabina u monoterapiji i intermitentnom liječenju iznosi 3000 mg/m2 dnevno, a 2000 mg/m2 dnevno kada se kapecitabin daje u kombinaciji s folinatnom kiselinom (30 mg oralno dvaput dnevno).
English: Grade 4 diarrhoea is an increase of ≥10 stools/day or grossly bloody diarrhoea or the need for parenteral support.
Croatian: Proljev 4. stupnja definira se kao porast broja stolica na  10 stolica dnevno ili pojava izrazito krvavih proljeva ili pak kao potreba za parenteralnom nadoknadom tekućine.
English: It is not known whether capecitabine is excreted in human breast milk.
Croatian: Nije poznato izlučuje li se kapecitabin u majčino mlijeko.
English: In lactating mice, considerable amounts of capecitabine and its metabolites were found in milk.
Croatian: U mlijeku mišica u fazi laktacije nađena je znatna količina kapecitabina i njegovih metabolita.
English: Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA).
Croatian: Dihidropiriminidaza cijepa pirimidinski prsten i nastaje 5fluoro-ureidopropionska kiselina (FUPA).
English: If these side effects continue, however, contact your doctor immediately.
Croatian: Ako se nuspojave ne povuku, odmah se obratite svom liječniku.